摘要
目的探讨多西紫杉醇(TXT)联合卡铂(CBP)治疗非小细胞肺癌(NSCLC)的剂量限制性毒性(DLT)和最大耐受剂量(MTD)。方法TXT按剂量递增分为65 mg／m2、75 mg／m2、85 mg／m2,第1天,静脉滴注,剂量递增至出现DLT;CBP以AUC定义为5计算剂量,第1天,静脉滴注,3周重复。结果16例NSCLC患者共完成54个周期化疗,中位周期数4个。15例患者可评价疗效,CR 1例,PR 7例,SD 3例,PD 4例。DLT为中性粒细胞减少,TXT的MTD为85 mg/m2。结论我们推荐TXT 75 mg／m2,CBP以AUC定义为5计算剂量,均为第1天使用,3周重复的方案作为初治NSCLC的化疗方案。
Objective To determine the maximum tolerated dose （MTD） and dose-limiting toxicity （DLT） of Docetaxel and Carboplatin in patients with non-small cell lung cancer. Methods Docetaxel was given at escalating doses until MTD was determined from the initial dose of 65 mg/m^2 to 75 mg/m^2, 85 mg/ m^2 on dl. Carboplatin was targeted to an area under the plasma concentration curve of 5 using Calver＇s equation on dl. The treatment cycle was repeated every 3 weeks. Results 16 patients received TXT and CBP for total of 54 courses （median four courses）. Neutropenia was the dose-limiting toxicity. The MTD of TXT is 85 mg/m^2. Conclusion We recommend TXT 75 mg/m^2 on dl and CBP with a target AUC of 5 on dl, 3weeks repeated for chemotherapy in naive patients with NSCLC.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2006年第12期946-948,共3页
Chinese Journal of Oncology
